Public or Private? | GenomeWeb

Public or Private?

Myriad CEO Peter Meldrum wrote into the New York Times in a June 20 letter, to highlight that while the Supreme Court invalidated the company's patent claims of isolated gene sequences, the court upheld several claims on synthetic DNA. In addition, he underscores the importance of diagnostic method patents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.

Japan needs to catch up on its gene-editing research efforts, the Japan News writes.

Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.

Jeff Huber, former Google X senior vice president, joins Grail as its CEO.